Johnson & Johnson-backed oncology company Aduro has closed a series D round that will be used to advance its pipeline of drug candidates.

Aduro Biotech, a US-based developer of treatments for pancreatic cancer backed by pharmaceutical company Johnson & Johnson, closed a $51.4m series D round yesterday.

Participants in the round included OrbiMed, Janus Capital Management, Jennison Associates, Foresite Capital Management, and funds managed by Franklin Advisers and Clough Capital Partners. Undisclosed existing investors including investment firm Morningside Group, as well as several undisclosed new investors, also participated.

Aduro previously raised $55m in a June 2014 series C round backed by Johnson &…